MGMT and central nervous system cancer: Through extensive examination of the molecular gene profile of individuals with glioma, researchers have discovered that certain molecular markers, such as isocitrate dehydrogenase 1 (IDH1) mutations and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, possess dual functionality as both prognostic indicators and criteria for assessing drug resistance [4,5].